Tuesday, 24 May 2005 - 2:05 PM
634

This presentation is part of: Proteinase

The Discovery and Development of Non-Covalent Cathepsin S Inhibitors

James P. Edwards, Johnson & Johnson Pharmaceutical Research and Development, San Diego, CA

The cysteine protease cathepsin S (CatS) has received much recent attention as a target for therapeutic intervention in a range of diseases of the immune system. CatS is expressed mainly in antigen-presenting cells and has been implicated in the presentation of antigens to CD4+ T-cells through the use of both knock-out animals and systemic administration of a peptidic, irreversible cysteine protease inhibitor, LHVS. The CatS inhibitors reported to date rely on covalent attachment of an electrophilic peptide-derived ligand to the active site thiol to achieve potent enzyme inhibition. In this presentation, the discovery, SAR investigations, and development of the first non-peptidic, non-covalent inhibitors of cathepsin S are described. Directed and high-through-put screening generated a set of CatS hits from which two lead structures were identified as promising starting points for a drug discovery effort. Lead optimization afforded potent (IC50 < 10 nM) and selective inhibitors of CatS demonstrating excellent cellular activity and good oral bioavailability and safety in pre-clinical species. The issues specific to this program that needed to be overcome to identify the clinical candidates will be discussed in detail.

Back to Proteinase
Back to The 37th Middle Atlantic Regional Meeting (May 22-25, 2005)